PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study

Autor: Benoit Gamain, Eleine Konaté, Alexis Kuppers, Gwenaelle Roguet, Myriam Kanté, Elvira Lopez-Perez, Amadou T. Konaté, Odile Launay, Issiaka Soulama, Moise Kabore, Linda Belarbi, Nicola K. Viebig, Florence Allais, Mathilde Bahuaud, Sodiomon B. Sirima, Cécilia Campion, Désiré Kargougou, Nadine Benhamouda, Amidou Ouedraogo, Arnaud Chêne, Nicolas Havelange, Valérie Boilet, Caroline Roussillon, San Maurice Ouattara, Pierre Loulergue, Rodolphe Thiébaut, Laura Richert, Eric Tartour, Hélène Espérou, Amidou Diarra, Aissata Barry, Odile Leroy, Frédéric Batteux, Alphonse Ouedraogo, Noelie Bere Henry, Issa Nebie, Jean-Philippe Semblat, Sébastien Dechavanne

Publikováno v: The Lancet Infectious Diseases
The Lancet Infectious Diseases, New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001-, 2020, 20 (5), pp.585-597. ⟨10.1016/S1473-3099(19)30739-X⟩
The Lancet Infectious Diseases, 2020, 20 (5), pp.585-597. ⟨10.1016/S1473-3099(19)30739-X⟩

PRIMVAC is a VAR2CSA-derived placental malaria vaccine candidate aiming to prevent serious clinical outcomes of Plasmodium falciparum infection during pregnancy. We assessed the safety and immunogenicity of PRIMVAC adjuvanted with Alhydrogel or gluco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6aea50e3acd648b0c8aab4deeff22fe5
https://pubmed.ncbi.nlm.nih.gov/32032567